AQST AQUESTIVE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, AQUESTIVE THERAPEUTICS INC reported revenue of $13.8M (up 38.1% from a year earlier), net income of −$22.9M and diluted EPS of −$0.18; over the last four quarters revenue was $54.1M and net income −$78.2M; for the fiscal year ended December 2025 revenue was $44.5M, down 22.6% on the year before.

AQST annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $44.5M, gross profit n/a, operating income −$71.1M, net income −$83.8M (margin -188.1%), EPS −$0.78
• Fiscal year ended Dec 2024: revenue $57.6M, gross profit n/a, operating income −$30.8M, net income −$44.1M (margin -76.7%), EPS −$0.51
• Fiscal year ended Dec 2023: revenue $50.6M, gross profit n/a, operating income −$15.1M, net income −$7.87M (margin -15.6%), EPS −$0.13
• Fiscal year ended Dec 2022: revenue $47.7M, gross profit n/a, operating income −$42.1M, net income −$54.4M (margin -114.1%), EPS −$1.12
• Fiscal year ended Dec 2021: revenue $50.8M, gross profit n/a, operating income −$34.7M, net income −$70.5M (margin -138.8%), EPS −$1.85

AQST quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $13.8M (up 38.1% year over year), net income −$22.9M, EPS −$0.18
• Quarter ended Mar 31, 2026: revenue $14.4M (up 65.7% year over year), net income −$8.06M, EPS −$0.07
• Quarter ended Dec 31, 2025 (from the annual report): revenue $13.0M (up 9.7% year over year), net income −$31.9M, EPS −$0.26
• Quarter ended Sep 30, 2025: revenue $12.8M (down 5.4% year over year), net income −$15.4M, EPS −$0.14
• Quarter ended Jun 30, 2025: revenue $10.0M (down 50.2% year over year), net income −$13.5M, EPS −$0.14
• Quarter ended Mar 31, 2025: revenue $8.72M (down 27.7% year over year), net income −$22.9M, EPS −$0.24
• Quarter ended Dec 31, 2024 (from the annual report): revenue $11.9M (down 10.1% year over year), net income −$17.1M, EPS −$0.18
• Quarter ended Sep 30, 2024: revenue $13.5M (up 4.2% year over year), net income −$11.5M, EPS −$0.13
• Quarter ended Jun 30, 2024: revenue $20.1M (up 51.8% year over year), net income −$2.75M, EPS −$0.03
• Quarter ended Mar 31, 2024: revenue $12.1M (up 8.3% year over year), net income −$12.8M, EPS −$0.17
• Quarter ended Dec 31, 2023 (from the annual report): revenue $13.2M (up 23.6% year over year), net income −$8.11M, EPS −$0.11
• Quarter ended Sep 30, 2023: revenue $13.0M (up 13.4% year over year), net income −$2.04M, EPS −$0.03
• Quarter ended Jun 30, 2023: revenue $13.2M (down 0.2% year over year), net income −$5.79M, EPS −$0.10
• Quarter ended Mar 31, 2023: revenue $11.1M (down 9.3% year over year), net income $8.07M, EPS $0.11
• Quarter ended Dec 31, 2022 (from the annual report): revenue $10.7M (down 3.6% year over year), net income −$12.4M, EPS −$0.21
• Quarter ended Sep 30, 2022: revenue $11.5M (down 13.7% year over year), net income −$12.5M, EPS −$0.23
• Quarter ended Jun 30, 2022: revenue $13.3M (down 13.6% year over year), net income −$16.3M, EPS −$0.36
• Quarter ended Mar 31, 2022: revenue $12.3M (up 10.3% year over year), net income −$13.2M, EPS −$0.32
• Quarter ended Dec 31, 2021 (from the annual report): revenue $11.1M, net income −$28.9M, EPS −$0.74
• Quarter ended Sep 30, 2021: revenue $13.3M, net income −$14.6M, EPS −$0.37

AQST cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$52.4M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$35.8M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$6.38M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$9.82M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$33.0M, share buybacks n/a

AQST balance sheet

• Jun 30, 2026: cash $98.5M, total assets $132M, total liabilities $189M, shareholders' equity −$56.6M
• Mar 31, 2026: cash $111M, total assets $141M, total liabilities $175M, shareholders' equity −$34.1M
• Dec 31, 2025: cash $121M, total assets $160M, total liabilities $194M, shareholders' equity −$33.7M
• Sep 30, 2025: cash $129M, total assets $164M, total liabilities $168M, shareholders' equity −$4.11M
• Jun 30, 2025: cash $60.5M, total assets $93.7M, total liabilities $166M, shareholders' equity −$72.6M
• Mar 31, 2025: cash $68.7M, total assets $102M, total liabilities $163M, shareholders' equity −$60.9M
• Dec 31, 2024: cash $71.5M, total assets $101M, total liabilities $162M, shareholders' equity −$60.2M
• Sep 30, 2024: cash $77.9M, total assets $110M, total liabilities $155M, shareholders' equity −$45.4M

What is AQST's revenue?

AQUESTIVE THERAPEUTICS INC reported $54.1M of revenue over its last four quarters, through June 30, 2026.

Is AQST profitable?

No. AQUESTIVE THERAPEUTICS INC lost $78.2M over the last four quarters.

What is AQST's EPS?

Diluted earnings per share over the last four quarters were −$0.65; −$0.18 in the latest quarter.

AQST ownership and insider trades · All stocks